Clinical trial
Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia: a Propensity Score Analysis
Name
AMED2019
Description
This study aims to assess whether ertapenem as an empiric treatment of third-generation-cephalosporin resistant Enterobacteriaceae (3GCRE) bacteremia is non-inferior to other carbapenems in term of 30-day mortality.
Trial arms
Trial start
2019-05-15
Estimated PCD
2021-12-31
Trial end
2022-10-01
Status
Completed
Treatment
Ertapenem
Ertapenem injection
Arms:
Ertapenem
Carbapenems
Other carbapenems injection
Arms:
Other carbapenems
Size
427
Primary endpoint
30-day mortality
30 days
Eligibility criteria
Inclusion Criteria:
* Adults, either sex, ages 18 years or above
* Patients with 3GCRE bacteremia
* Patients admitted to any of the study sites
Exclusion Criteria:
* Discontinuation of antibiotic due to transition to hospice care
* Polymicrobial bacteremia
* Empirical antibiotic after 24 hours of first evidence of bacteremia
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 427, 'type': 'ACTUAL'}}
Updated at
2023-03-29
1 organization
2 products
3 indications
Organization
Phramongkutklao College of Medicine and HospitalProduct
ErtapenemIndication
BacteremiaIndication
InfectionIndication
BacteriaProduct
Carbapenems